Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-12-18 / Vaccine 2011 Feb;29(6):1185-93Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2010-12-13 / J. Clin. Oncol. 2011 Jan;29(3):330-6Guiding the „misguided“ – functional conditioning of dendritic cells for the DC-based immunotherapy against tumours
/in Dendritic Cells, International Publications /von 2010-12-09 / Eur. J. Immunol. 2011 Jan;41(1):18-25Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy
/in Dendritic Cells, Glioblastoma, International Publications /von 2010-12-06 / Clin. Cancer Res. 2011 Mar;17(6):1603-15New approaches to the development of adenoviral dendritic cell vaccines in melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2010-12-01 / Curr Opin Investig Drugs 2010 Dec;11(12):1399-408Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-12-01 / Int. J. Oncol. 2010 Dec;37(6):1439-52Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2010-12-01 / Anticancer Res. 2010 Dec;30(12):5091-7
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution